A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer



Status:Recruiting
Conditions:Prostate Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:1/31/2019
Start Date:January 14, 2019
End Date:January 2022
Contact:Jordan Cisneros
Email:jordan.cisneros@stanford.edu
Phone:650-725-6409

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for
biopsy guidance in patients with suspected prostate cancer.

Primary Objective: To evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance
in patients with suspected prostate cancer.

Exploratory Objective:

- Correlation of 68Ga PSMA 11 uptake and Gleason score at biopsy

- Correlation of 68Ga RM2 and Gleason score at biopsy

Inclusion Criteria:

- Suspected prostate cancer

- Planned prostate biopsy

- Able to provide written consent

- Karnofsky performance status of 50 (or ECOG/WHO equivalent)

Exclusion Criteria:

- Patients not capable of getting PET study due to weight, claustrophobia, or inability
to lay still for the duration of the exam

- Metallic implants (contraindicated for MRI)
We found this trial at
1
site
Stanford University
450 Serra Mall
Stanford, California 94305
(650) 723-2300
Principal Investigator: Andrei H Iagaru, MD
Stanford University Stanford University, located between San Francisco and San Jose in the heart of...
?
mi
from
Stanford, CA
Click here to add this to my saved trials